Beiersdorf prelim sales, earnings down in 2009
This article was originally published in The Rose Sheet
Executive Summary
Hamburg, Germany-based firm records preliminary sales of €5.7 bil. ($8.3 bil.) for fiscal 2009, down 3.6 percent from the year prior. Sales in its consumer business segment, which includes Eucerin and NIVEA brands, were down 2.2 percent to €5.01 bil. ($7.2 bil.), though organic sales of the unit increased 1.2 percent. Although sales in Western Europe declined, revenues in the U.S., China and Latin America rose. Profit after taxes fell 33 percent to €379 mil. ($544.8 mil.). Beiersdorf's final results for the fiscal year will be released at an analyst meeting March 4
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.